Clinical Trial Update: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial studying LGX818 (dabrafenib) and cetuximab, or LGX818, BYL719 (alpelisib), and cetuximab in BRAF-mutant metastatic colorectal cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BYL719 (alpelisib)
• Cetuximab (cetuximab)
• LGX818 (encorafenib)

Snippet

Sponsor: Pfizer | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-06-23